| abstract |
Disclosed are antibodies that specifically bind to VLA-1 integrin, and methods of using these antibodies to treat immunological disorders. Also included are the crystal structures of the complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structural coordinates of these structures. In one aspect, the invention relates to an anti-VLA-1 antibody, wherein the light chain complementarity determining region of the VLA-1 antibody comprises amino acid residues 24-33, 49-55 and 88-96 of SEQ ID NO: 1. And the heavy chain complementarity determining regions of the VLA-1 antibody are defined by amino acid residues 31-35, 50-65 and 98-107 of SEQ ID NO: 2. |